Home>>Signaling Pathways>> Cell Cycle/Checkpoint>> Wee1>>MK-1775

MK-1775

Catalog No.GC16030

MK-1775 Chemical Structure

Wee1 kinase inhibtor,potent and ATP-competitive

Size Price Stock Qty
10mM (in 1mL DMSO)
$70.00
In stock
5mg
$62.00
In stock
10mg
$95.00
In stock
50mg
$283.00
In stock
100mg
$455.00
In stock

Customer Reviews

Based on customer reviews.

Tel: (626) 353-8530 Email: sales@glpbio.com

Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & SDS

View current batch:

Protocol

Kinase experiment [1]:

In vitro kinase assays

Recombinant human Wee1 was used. Kinase reaction was conducted with 10 μM ATP, 1.0 μCi of [γ-33P]ATP, and 2.5 μg of poly(Lys, Tyr) as a substrate in the presence of increasing concentrations of MK-1775 at 30 °C for 30 mins. Radioactivity incorporated into the substrate was trapped on MultiScreen-PH plates and was counted on a liquid scintillation counter.

Cell experiment [1]:

Cell lines

WiDr and H1299 cells

Preparation method

The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reaction Conditions

30, 100 or 300 nM; 24 hrs

Applications

The cotreatment with 30 and 100 nM of MK-1775 reduced the IC50 values of Gemcitabine to 21.5 and 7.1 nM, respectively. Similar potentiation of Gemcitabine was also observed in another p53-deficient lung cancer cell line, H1299.

Animal experiment [1]:

Animal models

Nude rats bearing WiDr, HeLa-luc or TOV21G-shp53 tumors

Dosage form

20 or 30 mg/kg; p.o.

Applications

In rats bearing WiDr tumors, MK-1775 treatment alone at 20 mg/kg displayed minimal antitumor effects with T/C of 69% at day 3. In rat bearing HeLa-luc and TOV21G-shp53 tumors, its antitumor efficacy is also moderate.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1]. Hirai H, Iwasawa Y, Okada M et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther. 2009 Nov;8(11):2992-3000.

Background

MK-1775 is a potent and selective Wee1 inhibitor with an IC50 of 5.2 nM in a cell-free assay. MK-1775 abolishes cyclin-dependent kinase 1 (CDC2) activity by phosphorylation of the Tyr15 residue [1]. Wee1 is a nuclearkinasebelonging to theSer/Thr familyof protein kinases. Wee1 kinase negatively regulates entry into mitosis by catalyzing the inhibitory tyrosine phosphorylation of CDC2/cyclin B kinase. Dysfunction of Wee1 will produce smaller than normal daughter cell [2].

In vitro:MK-1775 dose-dependently inhibited phosphorylation of CDC2 at tyr15 and abrogated the G2DNA damage checkpoint. MK-1775 inhibited Wee1 kinase in an ATP-competitive manner with an IC50 value of 5.2 nmol/L in the in vitro kinase assays. Compared to Wee1, MK-1775 displayed 2- to 3-fold less potency against Yes with the IC50value of 14 nM, 10-fold less potency against seven other kinases with >80% inhibition at 1 μM, and >100-fold selectivity over human Myt 1, another kinase that inhibited cyclin-dependent kinase 1 (CDC2) by phosphorylation at an alternative site (Thr14). By abrogating the DNA damage checkpoint via blockade of Wee1 activity in WiDr cells bearing mutated p53, MK-1775 treatment inhibited the basal phosphorylation of CDC2 at Tyr15 (CDC2Y15) with an EC50 of 49 nM, and dose-dependently suppressed gemcitabine-, carboplatin- or cisplatin-induced phosphorylation of CDC2 and cell cycle arrest, with the EC50 of 82 nM and 81 nM, 180 nM and 163 nM, as well as 159 nM and 160 nM, respectively. In WiDr and H1299 cells, MK-1775 treatment (30-100 nM)showed no significant antiproliferative effects, whereas MK-1775 at 300 nM was sufficient to inhibit Wee1 by >80%, displayed moderate but significant antiproliferative effects by 34.1% in WiDr cells and 28.4% in H1299 cells [1].

References:
[1].  Hirai H, Iwasawa Y, Okada M, et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents[J]. Molecular cancer therapeutics, 2009, 8(11): 2992-3000.
[2].  McGowan C H, Russell P. Cell cycle regulation of human WEE1[J]. The EMBO journal, 1995, 14(10): 2166.

Chemical Properties

Cas No. 955365-80-7 SDF
Synonyms MK1775,MK 1775
Chemical Name 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one
Canonical SMILES CC(C)(C1=NC(=CC=C1)N2C3=NC(=NC=C3C(=O)N2CC=C)NC4=CC=C(C=C4)N5CCN(CC5)C)O
Formula C27H32N8O2 M.Wt 500.6
Solubility ≥ 25.03mg/mL in DMSO Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

  • Molarity Calculator

  • Dilution Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).

Calculate

Reviews

Review for MK-1775

Average Rating: 5 ★★★★★ (Based on Reviews and 10 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for MK-1775

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.